ANDA 70161, held by Par Pharmaceutical. Tolazamide.
As of Nov 21, 2026, ANDA 70161 (Tolazamide), held by Par Pharmaceutical, was first approved by FDA on Jan 6, 1986, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 6, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tolazamide500MG · tablet;oral | Tolazamide | Discontinued |
| Jul 8, 1997 | Supplement 11Manufacturing | Approved | None posted |
| May 21, 1992 | Supplement 10Labeling | Approved | None posted |
| Feb 19, 1992 | Supplement 9Labeling | Approved | None posted |
| Aug 6, 1987 | Supplement 2Manufacturing | Approved | None posted |
| Feb 5, 1987 | Supplement 7Manufacturing | Approved | None posted |
| Jun 30, 1986 | Supplement 1Manufacturing | Approved | None posted |
| Jan 6, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters